


PHARMACEUTICAL 2021



PHIBRO ANIMAL HEALTH CORP Rank 97 of 409







RealRate

PHARMACEUTICAL 2021



PHIBRO ANIMAL HEALTH CORP Rank 97 of 409

The relative strengths and weaknesses of PHIBRO ANIMAL HEALTH CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PHIBRO ANIMAL HEALTH CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 467% points. The greatest weakness of PHIBRO ANIMAL HEALTH CORP is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 288% points.

The company's Economic Capital Ratio, given in the ranking table, is 37%, being 391% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	451,837
Cost of Goods Sold	543,472
Intangible Assets	123,676
Liabilities, Current	157,238
Liabilities, Non-Current	70,401
Other Assets	60,478
Other Compr. Net Income	-44,204
Other Expenses	21,960
Other Liabilities	368,257
Other Net Income	-13,682
Property and Equipment	148,109
Research and Development	0
Revenues	800,354
Selling, General and Administrative Expense	187,688

Output Variable	Value in 1000 USD
Assets	784,100
Liabilities	595,896
Expenses	753,120
Stockholders Equity	188,204
Net Income	33,552
Comprehensive Net Income	11,450
Economic Capital Ratio	37%

